Hanmi Pharmaceuticals is at the forefront of innovative drug development, focusing on several advanced technologies to address various therapeutic areas. One of their key technologies is the long-acting platform technology, which enables the creation of medications that provide sustained therapeutic effects over extended periods. This technology is exemplified by efocipegtrutide, a triple agonist targeting glucagon, gastric inhibitory peptide (GIP), and glucagon-like peptide-1 (GLP-1). This compound has shown promising results in reducing liver fat and improving inflammation and fibrosis in preclinical studies, particularly for conditions like metabolic dysfunction-associated steatohepatitis (MASH). The company is also exploring the potential of this technology for other fibrotic diseases, having received orphan drug designations from regulatory authorities.

In addition to their long-acting platform, Hanmi Pharmaceuticals is leveraging bispecific antibody platform technology, which allows for the development of drugs that can simultaneously target multiple pathways, enhancing therapeutic efficacy in oncology. This approach is particularly relevant in the context of cancer research, where the company is developing innovative treatments that utilize bispecific antibodies to engage multiple targets. Their commitment to research and development is further underscored by their open innovation strategy, which fosters collaboration with various stakeholders, including academic institutions and other companies, to accelerate the discovery and development of new therapies. This collaborative approach is integral to Hanmi's mission of leading advancements in the biopharmaceutical industry.

South Korea

Hanmi Pharmaceutical, Co., Ltd., headquartered in Seoul, South Korea, and established in 1973, has become one of the largest companies not only in Korea but also within the region, selling over 200 products worldwide. Today, Hanmi is also recognized as the No.1 R&D investing company in Korea, spending over 10~15% of the company’s annual revenue in developing next generation Platform Technologies & NCE products. 

Hanmi Pharmaceuticals

Company Details